-
-
-
Loading
Loading
But a popular drug is doing damage at home
The venture-capital boom is a risk for investors—and a gift for everyone else
Bumper earnings are already in the bag. Now costs are rising, and growth could be slowing
The evidence so far is muddy, and points to at most a small effect